Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

@inproceedings{Armstrong2016GlucagonlikeP1,
  title={Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis},
  author={Matthew J Armstrong and Diana L. Hull and Kathy Guo and Darren Barton and Jonathan M. Hazlehurst and Laura L. Gathercole and Maryam Nasiri and Jinglei Yu and S. Charles Langford Gough and Philip N Newsome and J W Tomlinson},
  booktitle={Journal of hepatology},
  year={2016}
}
BACKGROUND & AIMS Insulin resistance and lipotoxicity are pathognomonic in non-alcoholic steatohepatitis (NASH). Glucagon-like peptide-1 (GLP-1) analogues are licensed for type 2 diabetes, but no prospective experimental data exists in NASH. This study determined the effect of a long-acting GLP-1 analogue, liraglutide, on organ-specific insulin sensitivity, hepatic lipid handling and adipose dysfunction in biopsy-proven NASH. METHODS Fourteen patients were randomised to 1.8mg liraglutide or… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 52 CITATIONS

Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice

  • American journal of physiology. Gastrointestinal and liver physiology
  • 2019
VIEW 19 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2015
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 14 Citations per year over the last 3 years

  • 4% Increase in citations per year in 2018 over 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

Glucocorticoids fail to cause insulin resistance in human subcutaneous adipose tissue in vivo.

  • The Journal of clinical endocrinology and metabolism
  • 2013
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…